Title : XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma.

Pub. Date : 2020 Sep 15

PMID : 32942564






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Approximately 96% of patients with glioblastomas (GBM) have IDH1 wildtype GBMs, characterized by extremely poor prognosis, partly due to resistance to standard temozolomide treatment. Temozolomide isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens